LONDON (Alliance News) - Investment company Imperial Innovations Group PLC on Tuesday said portfolio company Cell Medica has acquired Switzerland-based Delenex Therapeutics AG.
Cell Medica, a cellular immunotherapy company in which Imperial holds a 27% stake, did not provide financial details on the acquisition.
Delenex is a clinical stage biopharmaceutical company focused on developing antibody therapeutics.
"This acquisition, which is a major step forward for the business, combined with the recent collaboration with Baylor College of Medicine, serves to highlight the scale of Cell Medica's ambition," said Imperial Chief Executive Russ Cummings.
By Sam Unsted; samunsted@alliancenews.com; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
